
STROMUSC YK11 10mg For Bodybuilding CAS: 1370003-76-1
YK-11 stands as one of the most intriguing, debated, and misunderstood compounds within the experimental bodybuilding landscape. Marketed as a "myostatin inhibitor" and a steroidal Selective Androgen Receptor Modulator (SARM), its 10mg dosage form is prevalent. However, navigating its reality requires stripping away hype and confronting its complex, potent, and risky nature. This analysis provides a uniquely detailed, evidence-based perspective.
What is YK-11? Beyond the SARM Label:
●Core Identity: YK-11 (17α-Ethynyl-5α-androst-2-ene-17β-ol) is fundamentally a modified dihydrotestosterone (DHT) derivative. While often grouped with SARMs due to its selective intent, its steroidal backbone fundamentally differentiates it. Its defining proposed mechanism is partial inhibition of the myostatin gene (MSTN) via follistatin upregulation, alongside direct androgen receptor (AR) binding.
●The "SARM" Misconception: True SARMs are non-steroidal molecules designed for tissue selectivity (muscle/bone over prostate/skin). YK-11's steroidal structure inherently challenges this classification. Its selectivity profile is less predictable and potentially less favorable than classic SARMs like Ostarine or Ligandrol. Think of it more accurately as a "Myostatin-Inhibiting Anabolic Steroid" (MIAS).
●Molecular Action: It binds the AR, triggering anabolic signaling. Crucially, research (primarily in vitro and rodent models) suggests it uniquely interferes with the signaling pathway of myostatin – a potent negative regulator of muscle growth. By reducing myostatin's activity, YK-11 potentially allows for greater muscle fiber hypertrophy and potentially hyperplasia (increased fiber number), a mechanism distinct from most anabolics.


Defining Features: The Double-Edged Sword
●Unique Mechanism: The proposed dual-action (AR agonism + myostatin inhibition) is its primary allure. No other widely discussed bodybuilding compound claims this specific combination.
●Potency: Anecdotal reports and limited research suggest significant anabolic potential, potentially exceeding many traditional SARMs mg-for-mg. This potency is intrinsically linked to its risks.
●Steroidal Nature: This is its critical differentiator and primary risk amplifier. Unlike non-steroidal SARMs:
It possesses progestogenic activity, significantly increasing the risk of progestin-related side effects (gynecomastia via estrogen interaction, suppression).
○It is highly suppressive of the Hypothalamic-Pituitary-Testicular Axis (HPTA), comparable to mild steroids, necessitating Post Cycle Therapy (PCT).
○It undergoes hepatic metabolism (liver processing), posing hepatotoxicity risks.
○It can convert to estrogenic metabolites, contributing to estrogenic side effects.
●Lack of Human Data: This is the paramount caveat. Almost all mechanistic data and efficacy claims stem from cell cultures and rodent studies. Human pharmacokinetics, efficacy, and long-term safety profiles are virtually unknown. Anecdotes ≠ evidence.
Applications & Purported Benefits (Theoretical & Anecdotal):
●Enhanced Muscle Hypertrophy & Density: The primary goal. The myostatin inhibition hypothesis suggests potential for lean, dense, "hard" muscle gains exceeding typical SARM results, particularly in "stubborn" areas.
●Potential Hyperplasia: The holy grail for some. While robust evidence in humans is absent, the myostatin pathway's role in regulating muscle fiber number provides the theoretical basis. This is highly speculative.
●Increased Strength: Correlated with significant muscle gain and potential neural adaptations driven by androgen signaling.
●Fat Loss Support: Androgen signaling can boost metabolic rate and lipolysis. This is secondary to its anabolic effects and diet-dependent.
●Bone Density Support: AR activation typically benefits bone mineral density, though specific data on YK-11 is lacking.
The Harsh Reality: Risks and Side Effects (10mg Amplifies These)
●Severe HPTA Suppression: Expect significant drops in natural testosterone (LH/FSH suppression). PCT is mandatory, not optional. 10mg is a potent dose.
●Estrogenic & Progestogenic Side Effects: High risk of gynecomastia (even without significant aromatization, due to progestogenic activity), water retention, and mood swings. Estrogen control (SERMs like Tamoxifen, not AIs) is often necessary during the cycle.
●Hepatotoxicity: Liver strain is a documented risk with YK-11. Regular liver enzyme monitoring (ALT/AST) is crucial. Avoid alcohol and other liver-toxic substances.
●Cardiovascular Strain: Potential negative impacts on lipid profiles (lowered HDL, raised LDL), increased blood pressure, and elevated hematocrit. Cardiovascular health monitoring is essential.
●Androgenic Side Effects: Acne, accelerated hair loss (if predisposed), increased body hair growth, and potential aggression, though often less than traditional DHT derivatives.
●Joint/Tendon Discomfort: Anecdotal reports frequently cite unusual joint pain and tendon tightness, potentially linked to rapid changes in muscle size/tension or collagen synthesis impacts. This is a significant concern.
●Unknown Long-Term Effects: The complete lack of long-term human safety data is a massive risk factor.
Dosage & Cycle Structure (Proceed with Extreme Caution):
●The 10mg Conundrum: This is a common capsule/dosage found. Given its potency and steroidal nature, 10mg is considered a high dose. Starting lower (e.g., 5mg) is strongly advised for first-time users to assess tolerance. Experienced users often report side effects becoming prominent at 10mg.
●Cycle Length: Extremely short cycles are recommended due to toxicity and suppression. 6-8 weeks is the absolute maximum. 4-6 weeks is more prudent for a first cycle.
●Cycle Example (Advanced Users Only):
○Weeks 1-6: YK-11 - Start at 5mg/day. If tolerated after 1-2 weeks, consider increasing to 10mg/day. Split doses (e.g., 5mg AM, 5mg PM) may help stability. Crucially: Introduce a SERM like Tamoxifen (10-20mg/day) starting week 2-3 if any estrogenic/progestogenic symptoms appear (itchy/puffy nipples are a red flag).
○Weeks 7-12: PCT (See Section 7). Crucially, blood work (Testosterone, LH, FSH, Estradiol, Lipids, Liver Enzymes) is essential BEFORE, MID (optional but wise), and AFTER the cycle.
●Support Supplements: A comprehensive liver support complex (TUDCA, NAC, Milk Thistle), cardiovascular support (Fish Oil, CoQ10, Citrus Bergamot), joint support (Glucosamine, Chondroitin, MSM, Cissus), and a general health multivitamin are non-negotiable.
Half-Life: The Pharmacokinetic Mystery
●Estimated Range: Based on its steroidal structure and comparison to similar molecules, YK-11's half-life is estimated to be between 8-16 hours. This is significantly shorter than many injectable steroids but comparable to or slightly longer than some oral steroids.
●Implications: The relatively short half-life necessitates split daily dosing (e.g., twice a day) to maintain stable blood levels and potentially mitigate side effect spikes. Taking the full 10mg dose once daily is suboptimal.
Post Cycle Therapy (PCT): Essential Recovery
●Why Mandatory? YK-11 causes profound HPTA suppression. Without PCT, natural testosterone recovery will be slow and incomplete, leading to significant muscle loss, persistent low-T symptoms (fatigue, low libido, depression), and potential long-term endocrine disruption.
●Typical PCT Protocol (4-6 Weeks): A SERM-based approach is standard:
○Week 1-2: Tamoxifen Citrate (20mg/day) OR Clomiphene Citrate (50mg/day)
○Week 3-4: Tamoxifen Citrate (10mg/day) OR Clomiphene Citrate (25mg/day)
○*(Optional, but recommended if suppression was severe): Continue Tamoxifen (10mg/day) OR Clomiphene (25mg/day) for Weeks 5-6.*
●PCT Timing: Begin PCT 24-48 hours after the last YK-11 dose due to its relatively short half-life.
●PCT Support: Continue liver support during PCT. Adding a natural testosterone booster (like DAA) is common but its efficacy beyond placebo is debated. Post-PCT blood work (4-6 weeks after PCT ends) is critical to confirm HPTA recovery.
Clinical Data
|
Brand |
STROMUSC |
|
Trade names |
YK11; (17α,20E)-17,20-diene-21-carboxylic acid methyl ester |
|
CAS |
1370003-76-1 |
|
Molar mass |
430.541 |
|
Formula |
C25H34O6 |
|
Purity |
Above 98% |
|
Apprarance |
10mg*100 |
Any needs, please contact us
Email: Jasonraws106@gmail.com
WhatsApp: +86-15572565525
Telegram: +86-15871669785

Conclusion: YK-11 10mg - High Risk, Unproven Reward
YK-11 (10mg) represents a fascinating yet perilous frontier in experimental bodybuilding. Its unique proposed mechanism of myostatin inhibition combined with steroidal AR activation offers the theoretical potential for exceptional muscle growth and density. However, this potential comes shackled to severe realities:
1.It is a potent, suppressive steroid, not a benign SARM. The risks (liver toxicity, severe suppression, gyno, lipid/cardio issues, joint pain) are significant and well-documented anecdotally.
2.Human data is non-existent. Everything about dosage, efficacy, and long-term safety is extrapolated from animals or user reports – a dangerous foundation.
3.10mg is a high dose almost guaranteed to trigger notable side effects requiring on-cycle estrogen management and demanding a robust PCT.
4.The myostatin inhibition hype vastly outstrips the evidence. While a compelling theory, its magnitude and consistency in humans using YK-11 remain entirely unproven.
For the Bodybuilder: Using YK-11 10mg is a high-stakes gamble reserved for highly experienced individuals who fully understand and accept the substantial risks, have meticulous health monitoring protocols in place (bloodwork!), possess effective ancillaries (SERMs, liver support), and commit to a disciplined PCT. It is emphatically not a beginner or intermediate compound. The potential rewards remain largely theoretical and anecdotal, while the risks are concrete and potentially severe. Extreme caution, comprehensive preparation, and a sober assessment of the unknowns are paramount. The pursuit of muscle should never outweigh the imperative of long-term health.
Hot Tags: stromusc yk11 10mg for bodybuilding cas: 1370003-76-1, China stromusc yk11 10mg for bodybuilding cas: 1370003-76-1 manufacturers, suppliers, factory, RAD150, Andarine S4, RAD140 increase lean muscle mass, MK2866, MK2866 Treat Muscular Dystrophy and Osteoporosis, AC 262 Selective androgen receptor modulator
